Declaration for Patent Application

Docket Number: 1909.0030002/JAG/CMB

As a below named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled: Methods of Purifying Recombinant Human Erythropoietin from Cell Culture Supernatants,

the specification of which is attached hereto unless the following box is checked:

	olication Number <u>09/830,964</u>	; and licable).			
I hereby state that I have revi	ewed and understand the con referred to above.	tents of the above identified specification, in	above identified specification, including the claims, as		
acknowledge the duty to dis continuation-in-part applications and the national or PCT inter	R. § 1.56, including for of the prior application				
in patent, inventor's or plant brain at least one country other tha	eeder's rights certificate(s), on the United States of Americ for patent, inventor's or plant	119(a)-(d) or (f), or § 365(b) of any foreign r § 365(a) of any PCT international application, listed below and have also identified below breeder's rights certificate(s), or PCT internation priority is claimed.	on, which des	ignated	
Prior Foreign Application(s)			Priority	Claimed	
<u>P98 01 05610</u> 4(Application No.)	Argentina (Country)	6 November 1998 (Day/Month/Year Filed)	⊠ Yes	□ No	
P99 01 00680 (Application No.)	Argentina (Country)	23 February 1999 (Day/Month/Year Filed)	⊠ Yes	□ No	
Send Correspondence to:					
	1100 New	, GOLDSTEIN & FOX P.L.L.C. York Avenue, N.W. Suite 600 n, D.C. 20005-3934			
Direct Telephone Calls to:	(20	02) 371-2600			

Appl. No. 09/830,964 Docket No. 1909.0030002/JAG/CMB

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

	Full name of sole or first inventor	
	Signature of sole or first inventor	Date
	Residence	
ļ	Guevara 561 - 1427 Capital Federal, Argentina ARX Citizenship	
ļ	Argentina	
	Mailing Address	
	same as above	
11.		
	Full name of second inventor	
9	Marcelo Eduardo Criscuolo	
iiiji,. ,		Date
### ##################################	Residence	
H. H.	Guevara 349 - 1427 Capital Federal, Argentina ARX	
e e e e e e e e e e e e e e e e e e e	Citizenship Argentina	·
	Mailing Address same as above	
مر	Full name of third inventor Carlos Alberto Melo / // A	
	Signature of third inventor of	Date
	Signature of third inventor V 04/5EP/01	
	Residence Club de campo Rueyrredón, Panamericana Km 49 Cód. 1629 - Pilar - Buenos Aires, Argentina	A 17 ~
	Club de campo Rueyrredon, Panamericana km 49 Cod. 1029 - Pilar - Ruellos Aires, Algerichia Citizenship	ARX
	Argentina	
	Mailing Address	
	same as above	<u> </u>

Appl. No. 09/830,964 Docket No. 1909.0030002/JAG/CMB

Full name of fourth inventor Juan Ale jandro Vidal		
Signature of fourth inventor	· 09/24/01	Date
Residence Guise 1760, 9th Floor, Apartment A, 1425 Juenos Aires Argentina	ARX	
Citizenship Argentina		
Mailing Address same as above		

P:\USERS\Cbouchez\\1909\0030002\\1909003-2.dec
SKGF Rev. 5/16/01 mac

(Supply similar information and signature for subsequent joint inventors, if any)



ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: Carlos M. Carcagno, Marcelo Criscuolo, Carlos Melo and Juan A. Vidal, the undersigned inventors hereby sell and assign to Sterrenbeld Biotechnologie North America, Inc. (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es) ☐ for the United States of America (as defined in 35 U.S.C. § 100), ☐ and throughout the world,

(a) in the invention(s) known as Methods of Purifying Recombinant Human Erythropoietin from Cell Culture Supernatants for which application(s) for patent in the United States of America has (have) been executed by the undersigned on 1) Left 19, 2001 2) Left 11, 2001

3) Left 4, 2001 4) Left 24, 2001 also known as United States Application No. 09/830,964 , filed May 3, 2001), which is the U.S. National Phase of PCT/US99/26241, International Filing Date 8 November 1999 in any and all applications thereon, in any and all Letters Patent(s) therefor, and

- (b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and
- (c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that they have full right to convey the entire interest herein assigned, and that they have not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; David K.S.

Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michael A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; John M. Covert, Esquire, Registration No. 38,759; and Linda E. Alcorn, Esquire, Registration No. 39,588; all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: Signature of Inventor: Carlos M. Carcagno

Date: Marcelo Criscuolo

Diagnos M. Carcagno

Marcelo Criscuolo

Date: 04/SEP/01 Signature of Inventor: Carlos Melo

Date: V0/24/01 Signature of Inventor: Juan A. Vidal

P:\USERS\Cbouchez\1909\0030002\1909003-2.asg

DO NOT FORWARD TO ASSIGNMENT BRANCH NOT FOR RECORDATION

POWER OF ATTORNEY FROM ASSIGNEE WITH DELEGATION

Sterrenbeld Biotechnologie North America, Inc., a corporation of Delaware, having a principal place of business at 1209mOrange Street, Wilmington, Delaware 19801, is assignee of the entire right, title, and interest for the United States of America (as defined in 35 U.S.C. §100), by reason of an Assignment to the Assignee executed on Cept 19, Sept 11, Sept 24, 2001, 1et be fively of an invention known as Methods of Purifying Recombinant Human Erythropoietin from Cell Culture Supernatants (Attorney Docket No. 1909.0030002/JAG/CMB), which is disclosed and claimed in a patent application of the same title by the inventors Carlos M. Carcagno, Marcelo Criscuolo, Carlos Melo and Juan A. Vidal (said application filed on May 3, 2001 at the U.S. Patent and Trademark Office, having Application Number 09/830,964).

The Assignee hereby appoint the U.S. attorneys associated with CUSTOMER NUMBER 28393 to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith, such attorneys currently being: Robert Greene Sterne, Registration No. 28,912; Edward J. Kessler, Registration No. 25,688; Jorge A. Goldstein, Registration No. 29,021; David K.S. Cornwell, Registration No. 31,944; Robert W. Esmond, Registration No. 32,893; Tracy-Gene G. Durkin, Registration No. 32,831; Michele A. Cimbala, Registration No. 33,851; Michael B. Ray, Registration No. 33,997; Robert E. Sokohl, Registration No. 36,013; Eric K. Steffe, Registration No. 36,688; Michael Q. Lee, Registration No. 35,239; Steven R. Ludwig, Registration No. 36,203; John M. Covert, Registration No. 38,759; and Linda E. Alcorn, Registration No. 39,588. The Assignee hereby grants said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

The Assignee hereby authorizes the U.S. attorneys named herein to accept and follow instructions from Bio Sidus S.A.

as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and the Assignee. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by the Assignee.

Send correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. 1100 New York Avenue, N.W. Suite 600
Washington, D.C. 20005-3934
U.S.A.

Direct phone calls to 202-371-2600.

FOR: Sterrenbeld Biotechnologie North America, Inc.

SIGNATURE:

RY: 🏅 Marcelo L. Argüelles

TITLE: President

DATE: V October 3, 2001

P:\USERS\Cbouchez\1909\0030002\1909003-2.poa

Certificate Under 37 C.F.R. § 3.73(b)

Applicant: Carcagno et al.
Appl. No.: 09/830,964 (which is the U.S. National Phase of PCT/US99/26241) 35 U.S.C. § 371 Date: May 3, 2001
Entitled: Methods of Purifying Recombinant Human Erythropoietin from Cell Culture Supernatants
Sterrenbeld Biotechnologie North America, Inc. (Name of Assignee), a corporation (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is:
1. [x] the assignee of the entire right, title, and interest, or
2. [] an assignee of an undivided part interest
in the patent application/patent identified above by virtue of either:
A. [x] An Assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel to be recorded. Frame to be recorded, or for which a copy thereof is attached. OR
B. [] A chain of title from the inventor(s) of the patent application/patent identified above to the current assignee as shown below:
1. From: To: To: The document was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
2. From: To: To: The document was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
3. From: To: To: The document was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
[] Additional documents in the chain of title are listed on a supplemental sheet.
[x] Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302-302.8]
The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.
Date: 🗸 October 3, 2001
Name: Marcelo L. Argielles
Title: President
Signature: V MA
USERS/Cbouchez/1909/0030002\1909003-2.cer